Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection

Eur J Immunol. 2024 Jan;54(1):e2350633. doi: 10.1002/eji.202350633. Epub 2023 Oct 20.

Abstract

In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection in this group has been little studied. Here, we performed single-cell analysis of peripheral blood mononuclear cells from patients with three major autoimmune diseases (rheumatoid arthritis, psoriasis, or multiple sclerosis) during SARS-CoV-2 infection. We observed compositional differences between the autoimmune disease groups coupled with altered patterns of gene expression, transcription factor activity, and cell-cell communication that substantially shape the immune response under SARS-CoV-2 infection. While enrichment of HLA-DRlow CD14+ monocytes was observed in all three autoimmune disease groups, type-I interferon signaling as well as inflammatory T cell and monocyte responses varied widely between the three groups of patients. Our results reveal disturbed immune responses to SARS-CoV-2 in patients with pre-existing autoimmunity, highlighting important considerations for disease treatment and follow-up.

Keywords: Autoimmunity; COVID-19; Multiple sclerosis; Psoriasis; Rheumatoid arthritis.

MeSH terms

  • Autoimmune Diseases*
  • Autoimmunity
  • COVID-19*
  • Humans
  • Leukocytes, Mononuclear
  • Multiomics
  • SARS-CoV-2
  • Single-Cell Analysis